Abstract
Late recurrences after therapy are rare in primitive neuro-ectodermal tumor (PNET). Most recurrences occur within the first 2 years after therapy, although a small number of recurrences may occur up to 5 years after therapy. We present a rare case of a recurrence of PNET in a 31-year-old woman 17 years after her initial presentation. The potential biological implications of this late recurrence as well as responses to subsequent therapy, including temozolomide, are discussed.
Copyright 2001 S. Karger AG, Basel
MeSH terms
-
Adult
-
Alkaline Phosphatase / analysis
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Biomarkers, Tumor / analysis
-
Cerebellar Neoplasms / drug therapy
-
Cerebellar Neoplasms / secondary*
-
Cerebellar Neoplasms / surgery
-
Cervical Vertebrae*
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Dura Mater*
-
Female
-
Humans
-
Isoenzymes / analysis
-
Lumbosacral Region
-
Meningeal Neoplasms / drug therapy
-
Meningeal Neoplasms / radiotherapy
-
Meningeal Neoplasms / secondary*
-
Neoplasm Proteins / analysis
-
Neuroectodermal Tumors, Primitive / drug therapy
-
Neuroectodermal Tumors, Primitive / radiotherapy
-
Neuroectodermal Tumors, Primitive / secondary*
-
Phosphopyruvate Hydratase / analysis
-
Pinealoma / pathology*
-
Pinealoma / radiotherapy
-
Radiosurgery
-
Remission Induction
-
Sciatica / etiology
-
Spinal Neoplasms / drug therapy
-
Spinal Neoplasms / radiotherapy
-
Spinal Neoplasms / secondary*
-
Synaptophysin / analysis
-
Temozolomide
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents, Alkylating
-
Biomarkers, Tumor
-
Isoenzymes
-
Neoplasm Proteins
-
Synaptophysin
-
Vincristine
-
Dacarbazine
-
Cyclophosphamide
-
Alkaline Phosphatase
-
Phosphopyruvate Hydratase
-
Cisplatin
-
Temozolomide